单纯微波消融与其联合肝动脉化学栓塞治疗原发性肝癌的对比研究

Sole percutaneous microwave coagulation versus its combination with transcatheter arterial chemoembolization for treatment of primary hepatoma： a comparison study

目的对比观察单纯微波消融与微波消融联合经导管动脉化学栓塞治疗原发i生肝癌的疗效及不良反应。方法收集2008年6月至2011年6月的50例中晚期原发性肝癌患者资料。其中15例只接受微波消融治疗（单独微波消融组），其余35例则接受微波消融联合肝动脉化学栓塞（5-氟尿嘧啶1．0g，顺铂60mg）治疗（微波消融联合经导管动脉化学栓塞组）。对比分析两组的治疗效果及不良反应。计数资料用石。检验。结果单独微波消融组和微波消融联合经导管动脉化学栓塞组的客观有效率分别为40%和62．8％（P=0．136）；1、2年生存率分别为46．6%、71．4%（P=0．095）和26．％、42．8％（P=0．048）。两组患者均无严重不良反应。结论对于不能切除的原发性肝癌，微波消融联合肝动脉化学栓塞治疗的疗效优于单独微波治疗，是一种安全有效的治疗方法。

Objective To evaluate the efficacy and adverse effects of sole percutaneous microwave coagulation therapy （PMCT） compared to that of PMCT combining with transcatheter arterial chemoembolization （TACE） for the treatment of primary hepatoma. Methods A total of 50 patients diagnosed with primary hepatocellular carcinoma were recruited and divided into two groups. Group A included 15 patients only treated with PMCT. The other 35 ones falling into group B were treated with PMCT in combination with TACE. Analysis of therapeutic efficacy and adverse effects were conducted. Results The objective effect rates in group A and group B were 40.0% and 62.8%, respectively. There was no significant difference between the two groups（P = 0.136）. The one-year survival rates of the two groups were 46.6% and 71.4%,respectively（P = 0.095）;and the two- year survival rates were 26.7% and 42.8%,respectively （P = 0.048）. No grade III adverse effects or beyond were observed. Conclusion PCMT combining with TACE is safe and more effective in one-year survival than PCMT alone for the treatment of primary hepatocellular carcinoma.